120 related articles for article (PubMed ID: 7532507)
1. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human malignant B cells.
Pulczynski S
Leuk Lymphoma; 1994 Oct; 15(3-4):243-52. PubMed ID: 7532507
[TBL] [Abstract][Full Text] [Related]
2. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: an immunofluorescence and immunoelectron microscopy study.
Pulczynski S; Boesen AM; Jensen OM
Blood; 1993 Mar; 81(6):1549-57. PubMed ID: 7680920
[TBL] [Abstract][Full Text] [Related]
3. Modulation and intracellular transport of CD20 and CD21 antigens induced by B1 and B2 monoclonal antibodies in RAJI and JOK-1 cells--an immunofluorescence and immunoelectron microscopy study.
Pulczynski S; Boesen AM; Jensen OM
Leuk Res; 1994 Jul; 18(7):541-52. PubMed ID: 7517481
[TBL] [Abstract][Full Text] [Related]
4. Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.
Haagen IA; Geerars AJ; de Lau WB; Clark MR; van de Griend RJ; Bast BJ; de Gast BC
Blood; 1994 Jul; 84(2):556-63. PubMed ID: 7517719
[TBL] [Abstract][Full Text] [Related]
5. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).
Haagen IA; van de Griend R; Clark M; Geerars A; Bast B; de Gast B
Clin Exp Immunol; 1992 Dec; 90(3):368-75. PubMed ID: 1281055
[TBL] [Abstract][Full Text] [Related]
6. Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody.
Vervoordeldonk SF; Merle PA; van Leeuwen EF; van der Schoot CE; von dem Borne AE; Slaper-Cortenbach IC
Blood; 1994 Mar; 83(6):1632-9. PubMed ID: 7510146
[TBL] [Abstract][Full Text] [Related]
7. The CD24 antigen discriminates between pre-B and B cells in human bone marrow.
Duperray C; Boiron JM; Boucheix C; Cantaloube JF; Lavabre-Bertrand T; Attal M; Brochier J; Maraninchi D; Bataille R; Klein B
J Immunol; 1990 Dec; 145(11):3678-83. PubMed ID: 1700990
[TBL] [Abstract][Full Text] [Related]
8. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.
Uckun FM; Jaszcz W; Ambrus JL; Fauci AS; Gajl-Peczalska K; Song CW; Wick MR; Myers DE; Waddick K; Ledbetter JA
Blood; 1988 Jan; 71(1):13-29. PubMed ID: 3257143
[TBL] [Abstract][Full Text] [Related]
9. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Ward E; Mittereder N; Kuta E; Sims GP; Bowen MA; Dall'Acqua W; Tedder T; Kiener P; Coyle AJ; Wu H; Jallal B; Herbst R
Br J Haematol; 2011 Nov; 155(4):426-37. PubMed ID: 21902688
[TBL] [Abstract][Full Text] [Related]
10. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
Haagen IA
Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
[TBL] [Abstract][Full Text] [Related]
11. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
[TBL] [Abstract][Full Text] [Related]
12. Human Lyb-2 homolog CD72 is a marker for progenitor B-cell leukemias.
Schwarting R; Castello R; Moldenhauer G; Pezzutto A; von Hoegen I; Ludwig WD; Parnes JR; Dörken B
Am J Hematol; 1992 Nov; 41(3):151-8. PubMed ID: 1384316
[TBL] [Abstract][Full Text] [Related]
13. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL
Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109
[TBL] [Abstract][Full Text] [Related]
14. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
15. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
Press OW; Farr AG; Borroz KI; Anderson SK; Martin PJ
Cancer Res; 1989 Sep; 49(17):4906-12. PubMed ID: 2667754
[TBL] [Abstract][Full Text] [Related]
16. Constitutive endocytosis and degradation of CD22 by human B cells.
Shan D; Press OW
J Immunol; 1995 May; 154(9):4466-75. PubMed ID: 7722303
[TBL] [Abstract][Full Text] [Related]
17. B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking.
Chaouchi N; Vazquez A; Galanaud P; Leprince C
J Immunol; 1995 Apr; 154(7):3096-104. PubMed ID: 7534787
[TBL] [Abstract][Full Text] [Related]
18. AFTR: a fifth human B-cell-specific surface antigen.
Pesando JM; Stucki MA
Hum Immunol; 1990 Mar; 27(3):193-207. PubMed ID: 2341301
[TBL] [Abstract][Full Text] [Related]
19. Does CD34+ cell selection enrich malignant stem cells in B cell (and other) malignancies?
Reading CL
J Hematother; 1996 Apr; 5(2):97-8. PubMed ID: 8723783
[No Abstract] [Full Text] [Related]
20. Flow cytometric detection of CD10 (cALLA) on peripheral blood B lymphocytes of neonates.
Brady KA; Atwater SK; Lowell CA
Br J Haematol; 1999 Dec; 107(4):712-5. PubMed ID: 10606874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
